结肠癌患者血清和癌组织中Annexin A5表达的临床意义
|
摘要
目的探讨膜联蛋白A5(Annexin A5)在结肠癌患者血清及癌组织中的临床意义。方法选取2013年2月至2016年3月在我院治疗的结肠癌患者93例为观察组,同时同时期体检健康者40例作为对照组。采用酶联免疫吸附法(ELISA)测定两组血清Annexin A5水平,采用免疫组织化学法检测癌组织中Annexin A5表达。比较两组血清和结肠癌组织中Annexin A5水平,比较不同分期患者癌组织中Annexin A5阳性率,采用受试者工作曲线(ROC)分析血清Annexin A5诊断结肠癌的灵敏度和特异度。结果观察组血清Annexin A5为(0.184±0.043) ng/m L,明显高于对照组的(0.159±0.051) ng/m L(P<0.05);伴淋巴结转移患者Annexin A5阳性表达率为79.31%,明显高于无淋巴结转移患者的48.44%(P<0.05);Ⅲ～Ⅳ期患者Annexin A5阳性表达率为86.96%,明显高于Ⅰ～Ⅱ期患者的29.79%(P<0.05);结肠癌组织Annexin A5阳性表达患者血清Annexin A5为(0.215±0.044) ng/m L,明显高于阴性表达患者的(0.180±0.021) ng/m L(P<0.05);血清Annexin A5与组织表达有相关性(r=0.312,P<0.05);以血清Annexin A5>0.148ng/m L为诊断结肠癌临界值时,其灵敏度为83.90%,特异度为57.50%。结论结肠癌患者癌组织Annexin A5表达与临床病理学指标有一定的关系;血清Annexin A5含量与癌组织Annexin A5表达相关,血清Annexin A5有助于诊断结肠癌。
Objective To study the clinical significance of Annexin A5 expression in serum and cancer tissues of patients with colon cancer.Methods 93 cases of colon cancer patients from February 2013 to March 2016 who treated in our hospital,were as the observation group,40 healthy persons in the same period were as the control group,the levels of serum Annexin A5 in two groups were measured by ELISA method,and the expression of Annexin A5 in tumor tissues was detected by immunohistochemistry.The Annexin A5 levels in serum and colon cancer tissues between the two groups were compared.The positive rate of Annexin A5 in cancer tissues of patients with different stages was compared,the sensitivity and specificity of Annexin A5 in the diagnosis of colon cancer were analyzed by receiver operating curve( ROC). Results The serum Annexin A5 of observation group was( 0. 184 ± 0.043) ng/m L, which was significantly higher than that of control group with( 0.159± 0.051) ng/m L( P< 0.05); The positive expression rate of Annexin A5 in patients with lymph node metastasis was 79.31%,which was significantly higher than that of 48.44% in patients without lymph node metastasis( P<0.05); The positive expression rate of Annexin A5 in patients with stage III ～ IV was 86.96%,which was significantly higher than that of 29.79% in patients with stage Ⅰ ～ Ⅱ( P<0.05); Colon cancer tissue Annexin A5 positive expression patients serum Annexin A5 was( 0.215± 0. 044) ng/m L, which was significantly higher than that of( 0. 180 ± 0. 021) ng/m L in negative expression patients( P<0.05); The serum Annexin A5 and tissue expression had correlation( r = 0.312,P<0.05); The sensitivity was 83.90% and specificity was 57.50% in the diagnosis of colon cancer with the critical value of serum Annexin A5>0.148 ng/m L.Conclusion The expression of Annexin A5 in colon cancer tissue has a certain relationship with the clinical pathological indicators, there is relevant between serum Annexin A5 and Annexin A5 in cancer tissues,the serum Annexin A5 is helpful in the diagnosis of colon cancer.
Objective To study the clinical significance of Annexin A5 expression in serum and cancer tissues of patients with colon cancer.Methods 93 cases of colon cancer patients from February 2013 to March 2016 who treated in our hospital,were as the observation group,40 healthy persons in the same period were as the control group,the levels of serum Annexin A5 in two groups were measured by ELISA method,and the expression of Annexin A5 in tumor tissues was detected by immunohistochemistry.The Annexin A5 levels in serum and colon cancer tissues between the two groups were compared.The positive rate of Annexin A5 in cancer tissues of patients with different stages was compared,the sensitivity and specificity of Annexin A5 in the diagnosis of colon cancer were analyzed by receiver operating curve( ROC). Results The serum Annexin A5 of observation group was( 0. 184 ± 0.043) ng/m L, which was significantly higher than that of control group with( 0.159± 0.051) ng/m L( P< 0.05); The positive expression rate of Annexin A5 in patients with lymph node metastasis was 79.31%,which was significantly higher than that of 48.44% in patients without lymph node metastasis( P<0.05); The positive expression rate of Annexin A5 in patients with stage III ～ IV was 86.96%,which was significantly higher than that of 29.79% in patients with stage Ⅰ ～ Ⅱ( P<0.05); Colon cancer tissue Annexin A5 positive expression patients serum Annexin A5 was( 0.215± 0. 044) ng/m L, which was significantly higher than that of( 0. 180 ± 0. 021) ng/m L in negative expression patients( P<0.05); The serum Annexin A5 and tissue expression had correlation( r = 0.312,P<0.05); The sensitivity was 83.90% and specificity was 57.50% in the diagnosis of colon cancer with the critical value of serum Annexin A5>0.148 ng/m L.Conclusion The expression of Annexin A5 in colon cancer tissue has a certain relationship with the clinical pathological indicators, there is relevant between serum Annexin A5 and Annexin A5 in cancer tissues,the serum Annexin A5 is helpful in the diagnosis of colon cancer.
引文
[1]孔琦,王道明,胡凯峰,等.右半结肠癌行完整结肠手膜切除术和传统根治术近期疗效的分析[J].实用医学杂志,2015,31(6):959-961.
[2]刘建军,魏寿江.结肠癌术后肿瘤复发转移的影响因素及远期预后观察[J].中国现代普通外科进展,2017,20(1):69-70.
[3]秦琼,应建明,吕宁,等.DNA错配修复与结肠癌预后和疗效预测的相关性[J].中华肿瘤杂志,2014,36(11):844-848.
[4]胡俊杰,周志祥,梁建伟,等.左、右半结肠癌患者临床病理特点及预后差异分析[J].中华医学杂志,2015,95(28):2268-2271.
[5]龙军先,高丕尧,高枫,等.膜联蛋白A5在不同临床分期结肠癌患者中的表达及意义[J].广东医学,2014,32(13):2013-2015.
[6]冉勇.螺旋CT与超声结合在结肠癌诊断中应用价值[J].现代仪器与医疗,2013,19(5):21-23.
[7]曲艳红,杨家梅.5-氟尿嘧啶对HepG2肝癌细胞系中膜联蛋白和血管内皮生长因子表达的影响[J].中华消化杂志,2012,32(2):128-129.
[8]张成海,苏向前,崔明,等.淋巴结阴性结肠癌伴同时性肝转移患者的临床病理因素分析[J].中国肿瘤临床,2016,25(5):183-187.
[9]崔艳成,高志冬,韩龙,等.右半结肠癌淋巴结跳跃转移高危因素单中心前瞻性观察性研究[J].中国实用外科杂志,2015,22(6):659-663.
[10]高丕尧,李通,高枫,等.Annexin A5沉默对ERK1/2 MAPK-Bax凋亡通路影响和意义[J].中华肿瘤防治杂志,2015,22(18):1440-1444.
[11]刘殊,王士勇,梁春艳,等.结肠癌中NIBP阳性肿瘤浸润免疫细胞的数量与患者预后的关系[J].现代肿瘤医学,2016,24(9):1407-1410.
[12]郑浩轩,李文静,石萌,等.Fas通路的激活促进结肠癌细胞迁移侵袭[J].现代消化及介入诊疗,2013,18(2):67-71.
[13]Tsukamoto H,Tanida S,Ozeki K,et al. Annexin A2 Regulates ADisintegrin and Metalloproteinase 17-mediated Ectodomain Shed-ding of Pro–Tumor Necrosis Factor-αin Monocytes and ColonEpithelial Cells[J]. Inflammatory Bowel Diseases,2013,19(7):1365-1373.
[14]Jun-Xian L,Pi-Yao G,Feng G,et al.The expression and clinical sig-nificance of annexin A5 in colon cancer patients in different clinicalstages[J].Guangdong Medical Journal,2014,35(13):2013-2015.
[15]曹超,余秋艳.结肠癌中AnnexinⅠ蛋白的表达及其临床意义[J].中国医药指南,2013,34(20):639-642.
[16]袁虎方,李勇.膜联蛋白A7在常见消化系统肿瘤中的作用[J].肿瘤学杂志,2016,26(5):422-426.
[17]Sun C,Zhao A,Ji S,et al.Expression of Annexin A5 in serum andtumor tissue of patients with colon cancer and its clinical signifi-cance[J].World Journal of Gastroenterology,2017,23(39):7168-7173.
[18]Onozawa H,Saito M,Saito K,et al.Annexin A1 is involved in resist-ance to 5-FU in colon cancer cells[J]. Oncology Reports,2017,37(1):235-240.
[19] Kazmierczak P M,Burian E,Eschbach R,et al. Monitoring CellDeath in Regorafenib-Treated Experimental Colon Carcinomas UsingAnnexin-Based Optical Fluorescence Imaging Validated by Perfu-sion MRI[J].PLOS ONE,2015,10(9):452-454.
[20]Tristante E,Martínez C M,Jiménez S,et al.Association of a charac-teristic membrane pattern of Annexin A2 with high invasiveness andnodal status in colon adenocarcinoma[J]. Translational Research,2015,166(2):196-206.
[21]Zorluoglu A.Serum Annexin A2 Levels in Patients with Colon Canc-er in Comparison to Healthy Controls and in Relation to Tumor Pa-thology[J].Medical Science Monitor,2014,20(7):1801-1807.
[2]刘建军,魏寿江.结肠癌术后肿瘤复发转移的影响因素及远期预后观察[J].中国现代普通外科进展,2017,20(1):69-70.
[3]秦琼,应建明,吕宁,等.DNA错配修复与结肠癌预后和疗效预测的相关性[J].中华肿瘤杂志,2014,36(11):844-848.
[4]胡俊杰,周志祥,梁建伟,等.左、右半结肠癌患者临床病理特点及预后差异分析[J].中华医学杂志,2015,95(28):2268-2271.
[5]龙军先,高丕尧,高枫,等.膜联蛋白A5在不同临床分期结肠癌患者中的表达及意义[J].广东医学,2014,32(13):2013-2015.
[6]冉勇.螺旋CT与超声结合在结肠癌诊断中应用价值[J].现代仪器与医疗,2013,19(5):21-23.
[7]曲艳红,杨家梅.5-氟尿嘧啶对HepG2肝癌细胞系中膜联蛋白和血管内皮生长因子表达的影响[J].中华消化杂志,2012,32(2):128-129.
[8]张成海,苏向前,崔明,等.淋巴结阴性结肠癌伴同时性肝转移患者的临床病理因素分析[J].中国肿瘤临床,2016,25(5):183-187.
[9]崔艳成,高志冬,韩龙,等.右半结肠癌淋巴结跳跃转移高危因素单中心前瞻性观察性研究[J].中国实用外科杂志,2015,22(6):659-663.
[10]高丕尧,李通,高枫,等.Annexin A5沉默对ERK1/2 MAPK-Bax凋亡通路影响和意义[J].中华肿瘤防治杂志,2015,22(18):1440-1444.
[11]刘殊,王士勇,梁春艳,等.结肠癌中NIBP阳性肿瘤浸润免疫细胞的数量与患者预后的关系[J].现代肿瘤医学,2016,24(9):1407-1410.
[12]郑浩轩,李文静,石萌,等.Fas通路的激活促进结肠癌细胞迁移侵袭[J].现代消化及介入诊疗,2013,18(2):67-71.
[13]Tsukamoto H,Tanida S,Ozeki K,et al. Annexin A2 Regulates ADisintegrin and Metalloproteinase 17-mediated Ectodomain Shed-ding of Pro–Tumor Necrosis Factor-αin Monocytes and ColonEpithelial Cells[J]. Inflammatory Bowel Diseases,2013,19(7):1365-1373.
[14]Jun-Xian L,Pi-Yao G,Feng G,et al.The expression and clinical sig-nificance of annexin A5 in colon cancer patients in different clinicalstages[J].Guangdong Medical Journal,2014,35(13):2013-2015.
[15]曹超,余秋艳.结肠癌中AnnexinⅠ蛋白的表达及其临床意义[J].中国医药指南,2013,34(20):639-642.
[16]袁虎方,李勇.膜联蛋白A7在常见消化系统肿瘤中的作用[J].肿瘤学杂志,2016,26(5):422-426.
[17]Sun C,Zhao A,Ji S,et al.Expression of Annexin A5 in serum andtumor tissue of patients with colon cancer and its clinical signifi-cance[J].World Journal of Gastroenterology,2017,23(39):7168-7173.
[18]Onozawa H,Saito M,Saito K,et al.Annexin A1 is involved in resist-ance to 5-FU in colon cancer cells[J]. Oncology Reports,2017,37(1):235-240.
[19] Kazmierczak P M,Burian E,Eschbach R,et al. Monitoring CellDeath in Regorafenib-Treated Experimental Colon Carcinomas UsingAnnexin-Based Optical Fluorescence Imaging Validated by Perfu-sion MRI[J].PLOS ONE,2015,10(9):452-454.
[20]Tristante E,Martínez C M,Jiménez S,et al.Association of a charac-teristic membrane pattern of Annexin A2 with high invasiveness andnodal status in colon adenocarcinoma[J]. Translational Research,2015,166(2):196-206.
[21]Zorluoglu A.Serum Annexin A2 Levels in Patients with Colon Canc-er in Comparison to Healthy Controls and in Relation to Tumor Pa-thology[J].Medical Science Monitor,2014,20(7):1801-1807.